Table 2: Drug resistance reversion in Mtb isolates from three patients with MDR-TB during the treatment with FS-1.
| Patient |
Week of isolation* |
Antibiotics |
| Isomiazid |
Rifampicin |
Streptomycin |
Pyrazinamide |
Ethambutol |
Kanamycin |
Amikacin |
Capreomycin |
Oflaxacin |
Ethionamide |
Cycloserine |
| Isolates from patient #187 |
|
0 |
R |
R |
R |
R |
R |
S |
R |
S |
R |
R |
R |
|
1 |
R |
R |
R |
R |
S |
S |
S |
S |
R |
R |
S |
|
7 |
R |
R |
R |
R |
S |
S |
S |
R |
R |
R |
R |
|
9 |
R |
R |
R |
R |
S |
R |
S |
S |
R |
R |
S |
| Isolates from patient #252 |
|
0 |
R |
R |
R |
R |
R |
S |
S |
R |
R |
R |
R |
|
3 |
R |
R |
R |
R |
R |
S |
S |
S |
R |
R |
R |
|
9 |
R |
R |
R |
R |
R |
S |
S |
S |
R |
R |
R |
|
12 |
R |
R |
R |
R |
R |
S |
S |
R |
R |
R |
R |
| Isolates from patient #320 |
|
0 |
R |
R |
R |
R |
R |
R |
S |
S |
R |
R |
R |
|
2 |
R |
R |
R |
R |
R |
R |
R |
S |
R |
R |
S |
|
6 |
R |
R |
R |
R |
S |
S |
S |
R |
R |
R |
S |
|
7 |
R |
R |
R |
R |
S |
S |
S |
S |
R |
R |
S |
|
8 |
R |
R |
R |
R |
S |
S |
S |
R |
R |
R |
S |
R – resistant isolate; shaded S – sensitive isolate
*Weeks of isolation were counted from the day of beginning of the treatment with the antibiotics and FS-1. The week 0 indicates the isolates obtained from the patients prior to the treatment.